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Abstract 
Hepatic sinusoidal obstruction syndrome is commonly described in pediatric oncology as a 
complication of chemotherapy.  It has also been occasionally reported in adult cancer patients.  
Treatment is largely supportive with fluid restriction.  A 16-month-old girl with stage II Wilms 
tumor receiving post-nephrectomy chemotherapy with dactinomycin and vincristine devel-
oped hepatic sinusoidal obstruction syndrome with painful hepatomegaly, ascites with sig-
nificant weight gain, grossly deranged liver function, severe thrombocytopenia, and reversal of 
blood flow in the portal vein on Doppler sonography.  Treatment with N-acetylcysteine was 
followed by complete resolution of clinical signs and amelioration of laboratory abnormalities 
within 72 hours of treatment.  N-acetylcysteine is a safe and probably an effective treatment 
for dactinomycin-induced hepatic sinusoidal obstructive syndrome. 
Key words: Dactinomycin, Hepatic sinusoidal obstructive syndrome; N-acetylcysteine, Nephro-
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Introduction 
Hepatic sinusoidal obstruction syndrome (SOS), 
previously known as veno-occlusive disease, is a fre-
quent  complication  with  significant  mortality  after 
myeloablative chemotherapy and hematopoietic stem 
cell transplantation [1,2].  It is uncommon in the set-
ting of conventional chemotherapy but tends to hap-
pen  in  children  receiving  dactinomycin  treatment 
[3,4].    Hepatic  SOS  after  chemotherapy  is  usually 
treated with supportive care with meticulous atten-
tion to fluid balance and restriction.  While treatment 
with antithrombotic or fibrinolytic agents and other 
agents  has  been  attempted  with  variable  success  in 
hepatic SOS after stem cell transplantation [5,6], the 
efficacy of pharmacological intervention has not been 
systematically studied in dactinomycin-induced SOS.  
In this report, we describe a child with Wilms tumor 
who developed moderately severe SOS that resolved 
rapidly after treatment with N-acetylcysteine. 
Case Report 
A 16-month-old girl was receiving chemothera-
py  with  vincristine  and  dactinomycin  (Regimen 
EE-4A)  for  a  left-sided  Wilms  tumor,  clinicopatho-
logic stage II with favorable histology, after nephrec-
tomy.  No radiotherapy was required.  On the day she 
received  the  fifth  weekly  dose  of  vincristine 
(0.05mg/kg), exactly seven days after the second dose 
of dactinomycin (0.045mg/kg, single-dose), she was 
noted to have a falling platelet count of 51 × 109/L and 
hemoglobin  of  8.1  g/dL.    The  clinical  examination 
was otherwise unremarkable and she was discharged 
after  the  vincristine  injection  and  an  erythrocyte 
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transfusion.    In  the  evening  she  started  to  have  re-
peated vomiting with a temperature of 38°C.  She was 
re-admitted the next day with 5% dehydration.  There 
was no jaundice or hepatosplenomegaly.  Complete 
blood counts showed Hb 14.0 g/dL, white cell count 
6.76 × 109/L, and platelet 14 × 109/L.  Liver function 
was  deranged  with  alanine  transferase  (ALT)  of  74 
u/L and aspartate transferase (AST) of 214 u/L but 
normal albumin (41 g/L) and bilirubin (19 µmol/L) 
levels.    Her  general  condition  improved  after  fluid 
resuscitation  and  the  vomiting  stopped  after  treat-
ment with intravenous granisetron. 
 On  the  third  day  of  admission,  her  condition 
deteriorated with recurrence of vomiting, abdominal 
pain,  and  abrupt  onset  of  ab-
dominal  distention,  with  a 
weight gain of 0.5 kg from the 
baseline of 9.5 kg.  The liver was 
palpable at 3 cm below the cos-
tal margin and was firm in con-
sistency.  Spleen tip and signs of 
shifting  dullness  were  detecta-
ble.  There was persistent severe 
thrombocytopenia despite platelet transfusion on the 
day of admission.  Serum ALT and AST were grossly 
elevated at 746 u/L and 1,660 u/L, respectively, and 
albumin dropped to 26 g/L.  Prothrombin time was 
prolonged  at  16.7  s  (normal,  10-14  s)  while  partial 
thromboplastin time (40.7 s) was still within normal 
limits.  An urgent ultrasonography and Doppler ex-
amination of the liver revealed hepatosplenomegaly 
and gross ascites.  Blood flow in the portal vein was 
reversed (Fig. 1).  The resistance in the hepatic artery 
was increased with peak systolic velocity of 2.95 m/s 
(normal, 0.4 m/s) and a resistive index of 0.67.  Small 
bilateral pleural effusions were present. 
 
 
 
Figure  1.  A.  Trans-abdominal 
sonography and Doppler study of 
the right lobe of the liver showing 
centrifugal blood flow in the main 
portal vein (in blue) compared to 
the hepatic arterial blood flow (in 
red).  B. Doppler study of the he-
patic  artery  showing  a  markedly 
increased peak velocity of 2.95 m/s. 
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Figure 2. Serial measurements of serum aspartate transaminase (AST, u/L, ), alanine transaminase (ALT, u/L, ), albumin 
(g/L, ), and platelet counts (× 10
9/L, ) from admission on Day 1 and discharge on Day 6, and follow-up testing on Day 13.  
Platelet transfusion () and albumin infusion with diuretic () were given. 
 
Hepatic  SOS  associated  with  dactinomycin 
treatment was diagnosed.  Feeding was stopped, fluid 
intake  was  restricted,  diuretic  was  given  intermit-
tently, and she was empirically treated with intrave-
nous meropenem.  She received N-acetylcysteine in-
travenously  with  a  loading  dose  of  140  mg/kg  fol-
lowed by 70 mg/kg every 6 hours.  N-acetylcysteine 
was diluted to a concentrated of 2.8 mg/mL and each 
dose was given as a 1-hour infusion.  An apparent 
response was noticed on the next day when the liver 
enzymes were stabilized and the platelet count started 
to rise.  On the following day, resolution of the hepa-
tomegaly and ascites was obvious on clinical exami-
nation and the laboratory parameters were much im-
proved  (Fig.  2).    N-acetylcysteine  was  discontinued 
after three days of treatment.  By the sixth day of ad-
mission,  the  abnormal  abdominal  signs  had  disap-
peared and she was able to feed as normal.  Serum 
ALT and AST levels dropped to 507 u/L and 333 u/L, 
respectively, and platelet rose to 104 × 109/L.  Serum 
bilirubin  levels  remained  normal  during  the  hospi-
talization.  She completed the rest of the treatment on 
time and remained in first complete remission at 16 
months after diagnosis. 
Discussion 
Hepatic  sinusoidal  obstruction  syndrome  is  a 
well-recognized  complication  after  high-dose  chem-
otherapy  in  the  setting  of  hematopoietic  stem  cell 
transplantation [1,2].  Hepatic SOS after conventional 
chemotherapy is uncommon and is mostly limited to 
pediatric  patients  receiving  dactinomycin-based 
chemotherapy  for  Wilms  tumor  [3,4],  rhabdomyo-
sarcoma  [7],  and  occasionally  malignant  germ  cell 
tumor  [8].    Intensive  anti-leukemic  regimens  incor-
porating 6-thioguanine [9] also predispose to hepatic 
SOS.  It has rarely been reported in adult patients [10]. 
 Studies in animals and from histopathology of 
affected  patients  have  concluded  that  injury  to  the 
endothelial  cells  at  the  sinusoidal  surface  of  the 
hepatocytes as the initiating event [1,2].  Obliteration 
of  the  hepatic  venules  as  a  result  of  subendothelial 
edema and microthrombosis leads to severe hepatic 
congestion,  sinusoidal  dilatation,  and  eventually 
portal hypertension and hepatocyte injury and death.  
Because of the inherent risks of liver biopsy, hepatic 
SOS is often diagnosed on clinical ground.  The Seattle 
criteria define hepatic SOS as a complication of stem 
cell transplantation when a patient develops two out 
of  the  three  clinical  features  within  21  days  of  the 
transplant: (1) jaundice, (2) painful hepatomegaly, and 
(3) ascites or weight gain of > 2% from baseline body 
weight.    The  findings  of  portal  hypertension  or  re-
versed flow in the portal vein support the diagnosis of 
hepatic SOS but this is only seen in advanced disease. 
 About  8%  or  41  out  of  511  children  receiving 
chemotherapy  for  Wilms  tumor  under  the  Interna-
tional Society of Pediatric Oncology (SIOP) collabora- Journal of Cancer 2011, 2 
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tive studies developed hepatic SOS as defined by the 
Seattle criteria [3].  A German study reported an oc-
currence of SOS of 4.8% (23 cases) from 481 patients 
[11],  whereas  the  National  Wilms  Tumor  Study-4 
recorded an incidence of 1.5% (23 out of 1,509 chil-
dren)  [4].    A  recent  single-center  study  from  the 
Netherlands reported an incidence of 13.2% or 12 out 
of 91 children from pre-operative chemotherapy and 
who had undergone liver biopsy during nephrectomy 
[12].  Children less than one year of age, those with 
right-sided tumor, or those receiving abdominal ra-
diotherapy are especially vulnerable to the complica-
tion [3], although the current case shares none of these 
risk factors.  Hepatic SOS typically appears after the 
second to sixth dose of dactinomycin, at seven to 14 
days after the last dose [7].  Unlike stem cell transplant 
recipients  who  fare  20-50%  mortality  [2],  children 
with  chemotherapy-induced  SOS  generally  recover 
after a period of 6-180 (median 22) days [3].  Ludwig 
et al. [11] reported a mortality of 8.7% with two deaths 
out of 23 cases.  Otherwise, fatal cases including an 
adult patient with Wilms tumor, are rarely reported 
[10,13-15]. 
 Hepatic SOS complicating the treatment of con-
ventional chemotherapy is often managed with sup-
portive care alone with cautious treatment for fluid 
retention.  In the setting of hematopoietic stem cell 
transplantation,  however,  antithrombotic  or  fibrino-
lytic  therapies  including  recombinant  tissue  plas-
minogen  activator,  heparin,  prostaglandin  E2,  an-
tithrombin III, and defibrotide have been attempted 
[5].  Recent studies suggest that defibrotide may be a 
safe and effective treatment for hepatic SOS [16] but 
the agent is expensive and not widely available.  NAC 
has been widely used for the treatment of hepatotoxi-
city  associated  with  paracetamol  poisoning  with  a 
good safety profile and manageable side effects [17].  
NAC  stimulates  the  production  of  glutathione  and 
scavenges  free  oxygen  radicals.    In  the  laboratory, 
animals  pretreated  with  glutathione  or  glutathione 
monoethyl  ester  are  less  susceptible  to  the  lethal 
hepatoxic  effects  of  BCNU,  cyclophosphamide,  and 
mitomycin C [18].  NAC has been reported to be ben-
eficial in the treatment of hepatic SOS following stem 
cell transplantation [6] and has been used with some 
success  in  the  authors’  institution  (unpublished  ob-
servation).    It  was  therefore  used  as  an  adjunct  to 
supportive care in the reported case.  Despite the ad-
vanced sonographic features, treatment with NAC in 
this case was followed by a rapid amelioration of the 
clinical and laboratory parameters of the liver disease. 
 Pharmacologic  intervention  for  chemothera-
py-induced hepatic SOS has previously been reported 
in nine cases (Table 1) [19-23].  The therapeutic agents 
include  anticoagulants  such  as  defibrotide,  an-
tithrombin  III,  heparin,  protein  C  concentrate,  and 
gabexate mesylate alone or in various combinations.  
High-dose methylprednisolone and aspirin was used 
in  another  patient.    All  affected  children  recovered 
from  the  treatments  with  laboratory  improvements 
seen after 3 to 10 days of treatment.  Given the usually 
long duration of morbidity and potential lethality in 
children  treated  with  supportive  care  alone,  these 
reports suggest that pharmacologic intervention may 
have a beneficial role in dactinomycin-induced SOS.  
Nevertheless, two children who received antithrom-
bin  III  and  heparin  treatment  developed  clinically 
significant bleeding [22], while the child who received 
gabexate mesylate developed a hypersensitivity reac-
tion [21].   
Table 1. Reported cases of pharmacologic intervention in hepatic sinusoidal obstruction syndrome  in children receiving 
chemotherapy alone. 
Case  Sex/Age/ 
Primary disease 
Treatment of sinusoidal obstruction syn-
drome 
Outcome/Complications from Treatment  References 
1  Male/11 months 
Wilms tumor 
Defibrotide 
Protein C concentrate 
Recovered; laboratory improvement from Day 4.  19 
2  Male/5 years 
Wilms tumor 
Methylprednisolone, high-dose  Recovered; laboratory improvement from Day 6.  20 
3  Male/1 year 
Rhabdomyosarcoma 
Gabexate mesylate 
Heparin & Antithrombin III 
Recovered; laboratory improvement from Day 5. 
Hypersensitivity reaction to gabexate. 
21 
4  Male/7 months 
Wilms tumor 
Antithrombin III 
Heparin 
Recovered; laboratory improvement from Day 7. 
Bleeding secondary to heparin. 
22 
5  Male/22 months 
Wilms tumor 
Anti-hrombin III 
Heparin 
Recovered; laboratory improvement from Day 5. 
Bleeding secondary to heparin. 
22 
6  Female/20 months 
Acute leukemia 
Antithrombin III  
Heparin 
Recovered; laboratory improvement from Day 3.  22 
7  Three patients  Defibrotide 
(+ tissue plasminogen activator in 1 case) 
Recovered; laboratory improvement from Day 2 to 8  23 
7  Female/16 months 
Wilms tumor 
N-acetylcysteine  Recovered; laboratory improvement from Day 2.  This re-
port 
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In summary, NAC is a safe and may be a poten-
tially  effective  treatment  for  hepatic  SOS  when  the 
latter is diagnosed early. 
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